Humana Inc. $HUM Stock Holdings Cut by Amundi

Key Points

• Amundi has reduced its holdings in Humana Inc. by 13.9%, owning 394,643 shares valued at $104.8 million after selling 63,799 shares in Q1.
• Several institutional investors, including PDT Partners LLC and Focus Partners Advisor Solutions LLC, significantly increased their positions in Humana during the same period, highlighting ongoing interest among hedge funds.
• Humana's recent earnings report showed a miss with $6.27 EPS against a $6.32 consensus, while revenue rose 9.6% year-over-year to $32.39 billion.

Amundi trimmed its holdings in Humana Inc. (NYSE:HUM - Free Report) by 13.9% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 394,643 shares of the insurance provider's stock after selling 63,799 shares during the quarter. Amundi owned about 0.33% of Humana worth $104,770,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Cary Street Partners Investment Advisory LLC increased its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after acquiring an additional 46 shares during the last quarter. Riverview Trust Co bought a new position in Humana in the 1st quarter valued at $34,000. Garde Capital Inc. bought a new position in Humana in the 1st quarter valued at $36,000. Zions Bancorporation National Association UT bought a new position in Humana in the 1st quarter valued at $37,000. Finally, Whipplewood Advisors LLC grew its position in Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after acquiring an additional 147 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM stock traded up $2.47 during midday trading on Monday, hitting $310.39. The company had a trading volume of 1,147,341 shares, compared to its average volume of 1,355,815. The company's 50 day simple moving average is $262.79 and its 200 day simple moving average is $256.68. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $357.00. The stock has a market cap of $37.33 billion, a price-to-earnings ratio of 23.82, a PEG ratio of 1.81 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.1%. Humana's payout ratio is 27.17%.

Analyst Ratings Changes

A number of research firms have recently issued reports on HUM. Piper Sandler dropped their price target on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Bank of America raised their price objective on Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Barclays raised their price objective on Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a research report on Friday. Robert W. Baird dropped their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Finally, Sanford C. Bernstein raised their price objective on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $289.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.